Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Seligdar co-owners suspected of embezzling NPF funds

6/24/24 SELG

Yuzhuralzoloto has set the price of additional share issue placement

6/24/24 UGLD

Participants of Softline's SPO purchased more than 400 thousand shares

6/24/24 SOFL

LSR will build a premium eight-story hotel

6/24/24 LSRG

EU partially allowed import of Russian diamonds

6/24/24 ALRS

X5 Retail Group will update its dividend policy in early 2025

6/24/24 X5

Sovcombank creates NPF

6/24/24 SVCB

Arsagera started testing the Distributed analytics platform

6/21/24 ARSA

NCC converts client dollars and euros into roubles

6/21/24 MOEX

Launch of the second process line at Vysokoye mine is scheduled for July

6/21/24 UGLD